drugset
drugset / Trial / NCT02965248

Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)

NCT02965248 ↗

Phase 3 Unknown 147 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed or oxaliplatin versus no HIPEC in locally advanced colorectal cancer

Timeline

Start
2016-11
Primary completion
2021-11
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

colorectal cancer